Five-Year Safety of Avoiding Biopsy After Negative MRI in Prostate Cancer Pathways
Long-term data show RAPID MRI-directed pathway safely avoids unnecessary biopsies while maintaining low rates of clinically significant prostate cancer.
FDA Greenlights Niraparib–Abiraterone–Prednisone for BRCA2‑Mutated Metastatic Castration‑Sensitive Prostate Cancer: Implications and Practical Considerations
The FDA approved once‑daily niraparib plus abiraterone acetate and prednisone for adults with deleterious or suspected deleterious BRCA2‑mutated metastatic castration‑sensitive prostate cancer (CSPC), based on rPFS and interim overall survival benefits in the AMPLITUDE trial.
Longer Travel Time to Prostate Cancer Treatment Linked to Lower Mortality—Is Centralization the Explanation?
A large registry study found that men with prostate cancer who traveled ≥30 minutes to their treating facility had modestly lower all-cause and prostate cancer–specific mortality than those traveling <30 minutes, raising questions about care centralization, case mix, and access barriers.
NCI Working Group on Biochemically Recurrent Prostate Cancer: Trial Design Guidance for a PSMA Era
The NCI convened experts to provide clinical-trial design recommendations for biochemically recurrent prostate cancer in the era of PSMA PET, defining PSMA+BCR, high-risk criteria, imaging and data standards, endpoint suggestions, and a push toward deintensification to limit toxicity.
Balancing Benefit and Harm: How Long Should Androgen Deprivation Therapy Be Given With Radiotherapy for Localized Prostate Cancer?
An individual-patient data meta-analysis of 10,266 men shows nonlinear oncologic benefit from longer ADT with radiotherapy (diminishing beyond 9–12 months) but increasing other-cause mortality with long-term ADT; optimal duration should be individualized by risk group and competing risks.
Metformin Fails to Delay Progression on Active Surveillance for Low‑Risk Prostate Cancer — Unexpected Signal in Obese Men
The MAST phase III trial found no benefit of metformin (850 mg twice daily) versus placebo for delaying progression in men with low‑risk prostate cancer on active surveillance; a prespecified subgroup showed increased pathologic progression in obese patients.
Metformin Does Not Delay Progression on Active Surveillance for Low‑Risk Prostate Cancer — Unexpected Signal in Obesity
A randomized phase III trial (MAST) found metformin did not prolong progression‑free survival in men on active surveillance for low‑risk prostate cancer; an exploratory subgroup showed increased pathologic progression in obese patients.
Posted inClinical Updates news Oncology Urology
Metformin in Metastatic Hormone-Sensitive Prostate Cancer Undergoing Androgen Deprivation Therapy: Insights from the STAMPEDE Phase 3 Trial and Contemporary Evidence
Comprehensive review of metformin's role in metastatic prostate cancer with ADT highlights STAMPEDE trial's findings: no significant overall survival benefit but metabolic side-effect mitigation. Integration of other RCTs outlines nuanced effects on metabolic syndrome and progression outcomes.
Posted inDiabetes & Endocrinology news Urology
Metformin Did Not Prevent Metabolic Syndrome During ADT but Improved Weight, Waist and HbA1c: Findings from the PRIME Phase 3 Trial
In the PRIME randomized phase 3 trial, metformin did not significantly reduce metabolic syndrome incidence in men starting androgen deprivation therapy, but produced modest, clinically relevant reductions in body weight, waist circumference, and hemoglobin A1c.
Comprehensive Overview of the AMPLITUDE Trial Results on Niraparib and AAP in HRR-Deficient Prostate Cancer
The AMPLITUDE trial demonstrated that adding niraparib to abiraterone acetate plus prednisone significantly improves progression-free survival in HRR-deficient metastatic prostate cancer, with maintained quality of life and manageable safety in advanced clinical settings.
Talazoparib plus Enzalutamide Significantly Prolongs Survival in mCRPC: Final TALAPRO-2 Results Confirm Greatest Benefit in BRCA‑Altered Disease
Final TALAPRO-2 data show that adding talazoparib to enzalutamide improves overall survival and rPFS in metastatic castration‑resistant prostate cancer, with the largest benefit in BRCA1/2‑altered tumors; hematologic toxicity is common but manageable.
European Prostate Cancer Screening After 23 Years: Sustained Mortality Reduction and Improved Harm-Benefit Profile
The 23-year follow-up of the ERSPC confirms that PSA screening reduces prostate cancer mortality by 13%, with an improved harm-benefit ratio, supporting risk-based screening strategies to optimize outcomes.
Age-Dependent Benefits of Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Meta-Analysis
This meta-analysis reveals that systemic treatment intensification improves overall survival in metastatic hormone-sensitive prostate cancer, with greater benefits in younger men and nuanced effects in older men, especially based on disease volume.
Rethinking Gleason Grade Group 1 Prostate Cancer: Insights from a Large-Scale Cohort Study
This study highlights the heterogeneity of GG1 prostate cancer and its implications for classification and management strategies.
Enhancing Survival in Biochemically Recurrent Prostate Cancer: The Promising Role of Enzalutamide
This review highlights the recent findings from the EMBARK trial demonstrating improved overall survival with enzalutamide combined with leuprolide in high-risk recurrent prostate cancer.
Posted inOncology Specialties Urology
Cribriform Morphology’s Impact on Long-term Metastasis Risk in Prostate Cancer: Insights from the PROTECT Trial
A secondary analysis of the PROTECT trial reveals cribriform-positive prostate cancer significantly elevates 15-year metastasis risk, with radiotherapy plus neoadjuvant ADT reducing this risk more effectively than surgery or active monitoring.
Biparametric MRI Matches Multiparametric MRI for Prostate Cancer Diagnosis: Insights from the PRIME Trial
The PRIME trial demonstrates that biparametric MRI, omitting contrast enhancement, is noninferior to multiparametric MRI in detecting clinically significant prostate cancer, offering a faster, cost-effective alternative potentially transforming diagnostic pathways worldwide.
Posted innews Oncology Radiology Specialties Urology
PSMA PET-Guided Intensification of Salvage Radiotherapy Enhances Outcomes Post-Radical Prostatectomy: Insights from a Phase 2 RCT
A phase 2 randomized trial demonstrates that PSMA-PET-guided intensification of salvage radiotherapy after radical prostatectomy significantly improves failure-free survival without added toxicity.
How Often Should Men Have Sex? Harvard Study Links 21 Times a Month to Lower Prostate Cancer Risk
A large Harvard study finds that frequent ejaculation—about 21 times a month—is associated with a significantly reduced risk of prostate cancer among men, offering new insights into modifiable factors for prevention.
Posted inAI Clinical Updates Oncology Specialties Urology
AI Foundation Model Revolutionizes Non-Invasive Diagnosis and Grading of Prostate Cancer
A multidisciplinary Chinese team has developed an AI-driven MRI-pathology foundation model that enables accurate, non-invasive diagnosis and grading of prostate cancer, significantly improving clinical decision-making and reducing unnecessary biopsies.